JP7761372B2 - 対象におけるマイトファジーを改善するための方法 - Google Patents

対象におけるマイトファジーを改善するための方法

Info

Publication number
JP7761372B2
JP7761372B2 JP2019548677A JP2019548677A JP7761372B2 JP 7761372 B2 JP7761372 B2 JP 7761372B2 JP 2019548677 A JP2019548677 A JP 2019548677A JP 2019548677 A JP2019548677 A JP 2019548677A JP 7761372 B2 JP7761372 B2 JP 7761372B2
Authority
JP
Japan
Prior art keywords
urolithin
muscle
compound
subject
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510678A (ja
JP2020510678A5 (https=
Inventor
リンシュ，クリストファー
アンドリュー，ペネロペ
シング，アヌラーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazentis SA
Original Assignee
Amazentis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1703736.7A external-priority patent/GB201703736D0/en
Priority claimed from GBGB1706596.2A external-priority patent/GB201706596D0/en
Priority claimed from GBGB1707863.5A external-priority patent/GB201707863D0/en
Application filed by Amazentis SA filed Critical Amazentis SA
Publication of JP2020510678A publication Critical patent/JP2020510678A/ja
Publication of JP2020510678A5 publication Critical patent/JP2020510678A5/ja
Priority to JP2023076856A priority Critical patent/JP2023100870A/ja
Application granted granted Critical
Publication of JP7761372B2 publication Critical patent/JP7761372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
JP2019548677A 2017-03-08 2018-03-08 対象におけるマイトファジーを改善するための方法 Active JP7761372B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076856A JP2023100870A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1703736.7A GB201703736D0 (en) 2017-03-08 2017-03-08 Methods for improving mitophagy in subjects
GB1703736.7 2017-03-08
GB1706596.2 2017-04-25
GBGB1706596.2A GB201706596D0 (en) 2017-04-25 2017-04-25 Methods for improving mitophagy in subjects
GB1707863.5 2017-05-16
GBGB1707863.5A GB201707863D0 (en) 2017-05-16 2017-05-16 Methods for improving mitophagy in subjects
PCT/EP2018/055790 WO2018162651A1 (en) 2017-03-08 2018-03-08 Methods for improving mitophagy in subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076856A Division JP2023100870A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Publications (3)

Publication Number Publication Date
JP2020510678A JP2020510678A (ja) 2020-04-09
JP2020510678A5 JP2020510678A5 (https=) 2021-04-22
JP7761372B2 true JP7761372B2 (ja) 2025-10-28

Family

ID=61691937

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548677A Active JP7761372B2 (ja) 2017-03-08 2018-03-08 対象におけるマイトファジーを改善するための方法
JP2023076856A Pending JP2023100870A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076856A Pending JP2023100870A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Country Status (4)

Country Link
US (1) US11969408B2 (https=)
EP (2) EP3592425A1 (https=)
JP (2) JP7761372B2 (https=)
WO (1) WO2018162651A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
US20180256538A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Method for improving mitophagy in subjects
US20180256471A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
CA3206062A1 (en) 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
JP2022185501A (ja) * 2021-06-02 2022-12-14 株式会社ダイセル 閉経後の女性の筋肉の重量を増加させるための組成物
EP4452259A1 (en) * 2021-12-20 2024-10-30 Société des Produits Nestlé S.A. Compositions comprising urolithin for treating muscle decline and a kidney dysfunction
JP2025510123A (ja) 2022-03-22 2025-04-14 アマゼンティス エスアー 組成物
CA3258478A1 (en) * 2022-06-06 2023-12-14 Amazentis Sa Urolithines to improve heart function and health
AU2024279527A1 (en) * 2023-05-26 2026-01-15 Amazentis Sa Urolithin for improving performance in elite and sub-elite athletes
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
WO2024252410A1 (en) * 2023-06-09 2024-12-12 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive composition for enhancing activity of pink1/parkin pathway
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501764A (ja) 2010-12-23 2014-01-23 アマゼンティス エスアー ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
WO2015097231A1 (en) 2013-12-24 2015-07-02 Amazentis Sa Prodrugs of urolitihns and uses thereof
JP2015523362A (ja) 2012-06-27 2015-08-13 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02304080A (ja) 1989-05-17 1990-12-17 Toyo Pharma- Kk ６Ｈ―ジベンゾ［ｂ，ｄ］ピラン―６―オン誘導体，その製法及び用途
KR20000019718A (ko) 1998-09-15 2000-04-15 박호군 탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물
US20030078212A1 (en) 1998-10-30 2003-04-24 Jia-He Li Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
US7727563B2 (en) 1999-04-19 2010-06-01 Pom Wonderful, Llc Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans
US7611738B2 (en) 2005-05-24 2009-11-03 Pom Wonderful, Llc Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof
US20010047032A1 (en) 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6440436B1 (en) 2001-05-18 2002-08-27 Natreon Inc. Process for preparing purified shilajit composition from native shilajit
US20080039179A1 (en) 2001-06-27 2008-02-14 Seelig Jerald C Gaming display with moveable indicator and methods of use
WO2004073612A2 (en) * 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
ES2543981T3 (es) 2004-03-24 2015-08-26 The Regents Of The University Of California Purificaciones de elagitaninos
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060257337A1 (en) 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
BRPI0708318A2 (pt) 2006-02-28 2011-05-24 Paloma Pharmaceuticals, Inc. composições e uso de compostos para tratar doenças caracterizadas por proliferação celular e angiogênese
WO2007127263A2 (en) 2006-04-26 2007-11-08 The Regents Of The University Of California Therapeutic uses of urolithins
US8894993B2 (en) 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
US8017147B2 (en) 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US8367072B2 (en) 2006-12-08 2013-02-05 Polifenoles Naturales, S.L. Composition for treating obesity and method of using the same
US7972633B2 (en) 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
WO2008139123A2 (fr) 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
EP2033526A1 (en) 2007-09-07 2009-03-11 Probelte Pharma, S.A. Nutritional products comprising pomegranate extracts containing ellagitannins and their use
US20110021618A1 (en) 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
US7927633B2 (en) 2008-03-28 2011-04-19 Janiece Diane Swilling Adaptogenic tea
WO2009137859A1 (en) * 2008-05-15 2009-11-19 Alois Jungbauer Compounds for the treatment of metabolic syndrome and insulin resistance
WO2009153652A2 (en) 2008-06-19 2009-12-23 Avesthagen Limited An extract and a process thereof (pomplex)
US20100004334A1 (en) 2008-07-01 2010-01-07 Mead Johnson Nutrition Company Nutritional Compositions Containing Punicalagins
CN101301319A (zh) 2008-07-09 2008-11-12 中国科学院新疆理化技术研究所 石榴花多酚的制备方法及其应用
US20100055247A1 (en) 2008-08-29 2010-03-04 Tirrito Salvatore J Nutritional Compositions for Athletes
JP5385686B2 (ja) 2009-06-05 2014-01-08 サントリーホールディングス株式会社 血小板凝集抑制剤
WO2011011721A2 (en) 2009-07-24 2011-01-27 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
WO2012113835A1 (en) 2011-02-22 2012-08-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection
US20180256538A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Method for improving mitophagy in subjects
US20180256471A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501764A (ja) 2010-12-23 2014-01-23 アマゼンティス エスアー ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
JP2015523362A (ja) 2012-06-27 2015-08-13 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
WO2015097231A1 (en) 2013-12-24 2015-07-02 Amazentis Sa Prodrugs of urolitihns and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nature Medicine, 2016, 発行日, Vol.22, No.8, p.879-888
Neurochemistry International, 2017年02月21日, 発行日, Vol.109, p.202-209

Also Published As

Publication number Publication date
EP4566601A2 (en) 2025-06-11
JP2023100870A (ja) 2023-07-19
US20180256539A1 (en) 2018-09-13
US11969408B2 (en) 2024-04-30
EP3592425A1 (en) 2020-01-15
WO2018162651A1 (en) 2018-09-13
JP2020510678A (ja) 2020-04-09
EP4566601A3 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
JP7761371B2 (ja) 対象におけるマイトファジーを改善するための方法
JP7761372B2 (ja) 対象におけるマイトファジーを改善するための方法
US20240148690A1 (en) Compositions comprising urolithin compounds
AU2016202656B2 (en) Combination of components for the prevention and treatment of frailty
US11123407B2 (en) Nutritional composition for treating or preventing impaired mobility
HK40127507A (en) Methods for improving mitophagy in subjects
JP6851086B2 (ja) 栄養不良を処置するための組成物および方法
HK40127528A (en) Methods for improving mitophagy in subjects
CN110678175A (zh) 用于预防或治疗心脏增大和/或瓣膜性心脏病的中链脂肪酸
KR20250133322A (ko) 우롤리틴과 케톤체의 조합물
JP2006232815A (ja) 血中ＣｏＱ１０量を増加させる医薬組成物
TW201733572A (zh) 用於預防及治療第２型糖尿病之營養品組合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230626

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251016

R150 Certificate of patent or registration of utility model

Ref document number: 7761372

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150